Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing

Form Is Removing Uncertainty From GLP-1 Coverage, Helping Employers Manage Medication Costs While Supporting Employee Health

BOSTON--(BUSINESS WIRE)--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs.

This builds on Form’s work with both companies. Form was one of the first telemedicine obesity care providers included on Lilly’s digital healthcare platform, LillyDirect™, and was among the first selected for Novo’s NovoCare^® platform earlier this year.

Despite increasing awareness of the benefits of GLP-1 therapies, only 19% of companies with 200 or more workers currently cover these medications for weight loss, rising to just 43% among firms with 5,000 or more employees. In addition, 70% of employers cite cost unpredictability and market complexities as a reason not to consider adding GLP-1 coverage.

This employer-direct model offers predictable, transparent medication costs, streamlined benefits administration, and confidence that employees receive care aligned with their clinical needs. For employers who have declined to offer GLP-1 coverage, removed it from their benefits, or simply want to optimize their existing benefits offering, this solution provides transparent, predictable pricing and integrated clinical support.

Starting in early 2026, employers can offer access to obesity medications through Form Health’s programs, aligning treatment with employee needs to ensure safe, effective care while giving employers clear visibility into costs.

“At Novo Nordisk we want access to our medications to be easy and affordable, and we are excited to partner and innovate with all who share our ambition, including those creating new options for employer access,” said Ed Cinca, Senior Vice President, Marketing and Patient Solutions at Novo Nordisk. “On behalf of those who are living with obesity or overweight, our priority is to help ensure that authentic, FDA-approved Wegovy^® is accessible because we know the important role that our medicines can play in treatment for weight loss, CV risk, or MASH.”

"This is about meeting employers exactly where they are—whether they've never offered GLP-1 coverage or are looking to optimize their existing benefits,” said Evan Richardson, Founder & CEO of Form Health. "These new offerings deliver what employers tell us they need most: predictable costs, measurable outcomes, and clinical care that treats obesity as the chronic disease it is. We've removed the complexity and built a solution that works for both the employer's bottom line and their employees' health."

“Employers continue to tell us they want to better support their employees’ health but face real challenges in providing coverage for obesity management medicines like Zepbound,” said Kevin Hern, Senior Vice President, Lilly Employer, Lilly USA. “We’re excited to work with organizations that share our commitment to removing friction and providing flexible, transparent solutions for employers, to help expand access to obesity management medicines for people who need them.”

About Form Health

Form Health is the national leader in science-based obesity and cardiometabolic care, delivering comprehensive medical treatment that addresses obesity as the root cause of many chronic health conditions. Form provides physician-led care delivered by American Board of Obesity Medicine-certified clinicians and supported by specialized Care Teams, including Advanced Practice Providers and Registered Dietitians. This evidence-based approach combines personalized behavioral health support, nutrition guidance, physical activity programs, and FDA-approved medications, when appropriate. Form helps organizations navigate the rapidly evolving GLP-1 landscape while driving measurable outcomes—from reduced medical spending to improved employee productivity and retention. The result is lasting weight loss, improved cardiometabolic health, and guaranteed ROI for enterprise partners. Learn more at formhealth.co.